UK – Macfarlane Group, a packaging company based in Glasgow, has finalized the acquisition of Allpack Packaging Supplies, a protective packaging distributor, in a deal worth £3.25 million (US$4.14m).
This acquisition aligns seamlessly with Macfarlane’s strategic objective to bolster its protective packaging segment, combining both organic growth and strategic acquisitions.
Allpack, situated in East Anglia, England, near Bury St Edmunds, serves a diverse clientele across various sectors from its warehouse.
Post-acquisition, Allpack’s existing team, comprising three directors and seven employees, will continue operations without interruption.
Macfarlane anticipates that this acquisition, coupled with a series of previous acquisitions over the past year, will significantly contribute to enhancing its earnings.
While the financial specifics of the transaction remain undisclosed, Macfarlane CEO Peter Atkinson expressed enthusiasm about the deal, stating, “This latest transaction follows three acquisitions undertaken in the prior 12 months, and clearly demonstrates further progress in executing against our buy-and-build strategy.
“Allpack Packaging Supplies is a well-run, successful protective packaging distributor with an experienced management team.
“Their addition to the Macfarlane Group further strengthens our ability to serve customers in East Anglia. We look forward to working with the team at Allpack Packaging Supplies to support its continued growth.”
Myonex to acquire packaging and bioservices business of Creapharm
In a parallel development, global clinical trial supply company Myonex has announced its agreement to acquire the clinical, commercial packaging, and bioservices business of Creapharm. Creapharm, headquartered in Reims, France, with additional locations in Bordeaux, Bailly-Romainvilliers, France, and Marietta, USA, operates in the same domain.
This strategic move aims to amalgamate Myonex’s expertise in drug sourcing and clinical trial prescription services with Creapharm’s proficiency in clinical packaging and distribution.
The acquisition will notably augment Myonex’s capabilities in clinical packaging, labelling, distribution, and supply chain management, particularly for advanced therapy medicinal products.
However, the completion of this acquisition is contingent upon regulatory approval, and the financial terms have not been disclosed.
Myonex CEO James Lovett expressed optimism about the synergies between the two entities, stating, “By combining, we will fill a gap in the market with broad and deep expertise, integrated services, and extraordinary client focus.
“Myonex looks forward to combining with our Creapharm colleagues to meet the needs of our clients with agility and speed.”
Upon the transaction’s conclusion, Myonex will maintain its existing leadership structure, with Mike Cohen serving as executive chair and Lovett as CEO.
Concurrently, Creapharm CEO and founder Eric Placet will reinvest in Myonex and join its board of directors.
Placet remarked, “Growing with Myonex is an obvious step for Creapharm to move forward, contributing our expertise and wide range of packaging solutions to their operations while we will expand the range of services we offer in support of always more effective, efficient, patient-centric clinical trials.
“Creapharm is pleased to evolve the overall mission of Myonex through our complementary strengths and to provide scale and flexibility in meeting our clients’ needs.”
For all the latest packaging and printing industry news from Africa and the World, subscribe to our NEWSLETTER, follow us on LinkedIn and subscribe to our YouTube channel.
